{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:58:32Z","timestamp":1786366712010,"version":"build-2736575974"},"reference-count":32,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.25-0027","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T22:06:46Z","timestamp":1746742006000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["Promising Treatment Strategy for Primary Malignant Melanoma of the Esophagus by Radical Esophagectomy and Nivolumab as Adjuvant Therapy: A Case Report"],"prefix":"10.70352","volume":"11","author":[{"given":"Yusuke","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-0253","authenticated-orcid":false,"given":"Junya","family":"Kitadani","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hayata","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Goda","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinta","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Nakai","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Nagano","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kawai","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Li J, Guan W, Ren W, et al. Longitudinal genomic alternations and clonal dynamics analysis of primary malignant melanoma of the esophagus. Neoplasia 2022; 30: 100811.","DOI":"10.1016\/j.neo.2022.100811"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Dai L, Wang ZM, Xue ZQ, et al. Results of surgical treatment for primary malignant melanoma of the esophagus: a multicenter retrospective study. J Thorac Cardiovasc Surg 2021; 161: 294\u2013302.","DOI":"10.1016\/j.jtcvs.2020.03.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006\u201317.","DOI":"10.1056\/NEJMoa1414428"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Weber JS, D\u2019Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375\u201384.","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377: 1345\u201356.","DOI":"10.1056\/NEJMoa1709684"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Chang CY, Park H, Malone DC, et al. Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis. JAMA Netw Open 2020; 3: e201611.","DOI":"10.1001\/jamanetworkopen.2020.1611"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Endo F, Akiyama Y, Onishi M, et al. Primary esophageal malignant melanoma successfully treated with anti-PD-1 antibody for retroperitoneal recurrence after esophagectomy: a case report. Int J Surg Case Rep 2020; 75: 152\u20136.","DOI":"10.1016\/j.ijscr.2020.09.034"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hanada K, Tsunoda S, Nomura M, et al. A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. Surg Case Rep 2022; 8: 206.","DOI":"10.1186\/s40792-022-01561-z"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Nambara S, Sakaguchi Y, Tsuda Y, et al. Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab. Int Cancer Conf J 2022; 12: 100\u20133.","DOI":"10.1007\/s13691-022-00582-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Okamoto T, Nakano E, Yamauchi T. Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report. J Med Case Rep 2021; 15: 345.","DOI":"10.1186\/s13256-021-02928-w"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Ito S, Tachimori Y, Terado Y, et al. Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report. J Med Case Rep 2021; 15: 237.","DOI":"10.1186\/s13256-021-02821-6"},{"key":"12","unstructured":"12) Attlassy N, Agbeh A, Patnaik R, et al. Primary malignant melanoma of the gastroesophageal junction treated with immunotherapy: a case rep. WMJ 2023; 122: 77\u201380."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tsukamoto R, Ihara H, Takase M, et al. Immunotherapy against esophageal primary amelanotic malignant melanoma relapse. J Surg Case Rep 2021; 2021: rjab393.","DOI":"10.1093\/jscr\/rjab393"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Yamaguchi T, Fushida S, Kinoshita J, et al. A case of primary malignant melanoma of the esophagogastric junction with abscopal effect after nivolumab administration. Surg Case Rep 2021; 7: 253.","DOI":"10.1186\/s40792-021-01336-y"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shibayama R, Fujisawa K, Ogawa Y, et al. The first case of primary malignant melanoma of the esophagus to achieve pathologic complete response after preoperative ipilimumab + nivolumab followed by resection. Clin J Gastroenterol 2025; 18: 29\u201336.","DOI":"10.1007\/s12328-024-02050-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Rice TW, Patil DT, Blackstone EH. 8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg 2017; 6: 119\u201330.","DOI":"10.21037\/acs.2017.03.14"},{"key":"17","unstructured":"17) Baur EH. A case of primary melanoma of the esophagus. Arb Geb Pathol Anat Inst T\u00fcbingen 1906; 5: 343\u201354. (in German)"},{"key":"18","unstructured":"18) Sabanathan S, Eng J, Pradhan GN. Primary malignant melanoma of the esophagus. Am J Gastroenterol 1989; 84: 1475\u201381."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Iwasaki K, Ota Y, Yamada E, et al. Primary malignant melanoma of the esophagus with multiple lymph node metastases: a case report and literature review. Medicine (Baltimore) 2020; 99: e18573.","DOI":"10.1097\/MD.0000000000018573"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Volpin E, Sauvanet A, Couvelard A, et al. Primary malignant melanoma of the esophagus: a case report and review of the literature. Dis Esophagus 2002; 15: 244\u20139.","DOI":"10.1046\/j.1442-2050.2002.00237.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Iwanuma Y, Tomita N, Amano T, et al. Current status of primary malignant melanoma of the esophagus: clinical features, pathology, management and prognosis. J Gastroenterol 2012; 47: 21\u20138.","DOI":"10.1007\/s00535-011-0490-y"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Wang X, Kong Y, Chi Z, et al. Primary malignant melanoma of the esophagus: a retrospective analysis of clinical features, management, and survival of 76 patients. Thorac Cancer 2019; 10: 950\u20136.","DOI":"10.1111\/1759-7714.13034"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Tsuyama S, Kohsaka S, Hayashi T, et al. Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus. Histopathology 2021; 78: 240\u201351.","DOI":"10.1111\/his.14210"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Lasota J, Kowalik A, Felisiak-Golabek A, et al. Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors. Mod Pathol 2019; 32: 957\u201366.","DOI":"10.1038\/s41379-018-0163-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320\u201330.","DOI":"10.1056\/NEJMoa1412082"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824\u201335.","DOI":"10.1056\/NEJMoa1709030"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 2023; 29: 2835\u201343.","DOI":"10.1038\/s41591-023-02583-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350: 207\u201311.","DOI":"10.1126\/science.aad0095"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191\u2013203.","DOI":"10.1056\/NEJMoa2032125"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Furune S, Kondo C, Takano Y, et al. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment. Int Cancer Conf J 2022; 11: 46\u20138.","DOI":"10.1007\/s13691-021-00515-w"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Inadomi K, Kumagai H, Arita S, et al. Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus. Medicine (Baltimore) 2016; 95: e4283.","DOI":"10.1097\/MD.0000000000004283"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kashfi S, Marneni N, Sharma S, et al. Primary malignant melanoma of the esophagus in a 76-year-old female. Cureus 2022; 14: e23250.","DOI":"10.7759\/cureus.23250"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0027\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:14:21Z","timestamp":1746850461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0027\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0027","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.25-0027"}}